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inhibitors in Norway. Pharmacoeconomic analyses also show that large financial
resources would be saved if the structure of the utilized ACE inhibitors in Serbia
were more similar to the one in Norway.
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OBJECTIVES: Around 800,000 patients are diagnosed for atrial fibrillation (AF) in
France with an increased risk of strokes. For many of them, prevention with anti-
coagulant is managed in primary care. Prevention should be driven by individual
risk for stroke estimated with a score (CHADS2) ranging from 0 (lower risk) to 6
(higher risk). This study was to describe AF patients’ management by general prac-
titioners (GP). METHODS: This cross-sectional study analyzed a medical files and
prescriptions database of a representative sample of 1,200 GPs. Data from all pa-
tients present in the database from July-2010 to June-2011, with a diagnosis of AF
and aged 18 and above were extracted. Based on age (75), comorbidities (HTA/
Diabetes) and history of stroke/TIA/CHF, CHADS2 was calculated for all patients.
Under-treatment status was defined according European guidelines which recom-
mend prevention with aspirin or vitamin-K antagonists (VKA) for CHADS21 and
VKA for CHADS22. RESULTS: A total of 15,623 AF patients were identified. Mean
age was 74.6(11.1) years old, 59.5% were men and mean CHADS2 was 1.5(1.1).
12,985 patients (83.1%) were found eligible for stroke prevention (i.e.CHADS21).
Among them, 23.4% received no prevention at all, 11.4% were under-treated (i.e.
aspirin instead of VKA) and 4.7% received non-recommended treatment (i.e. clopi-
dogrel). Within patients with CHADS21 (n5,026), 26.7% had no treatment, 48.9%,
20.5% and 3.9% were treated with VKA, aspirin and clopidogrel, respectively.
Within those with CHADS2 (n7,959), only 54.9% received VKA when 21.3% had
no treatment and 18.6% and 5.1% were prescribed aspirin and clopidogrel,
respectively. CONCLUSIONS: In this large study in French primary care, four out of
five (83.1%) of patients diagnosed with AF should benefit from stroke prevention.
Overall, around 45% of thromboembolic high-risk patients (i.e.CHADS22) were
not treated or inadequately treated. Future analyses should be performed to inves-
tigate the gap between clinical practice and guidelines.
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OBJECTIVES: The risk of cardiovascular disease (CVD) is reported to be 2-4 times
higher in patients with type 2 diabetes mellitus (T2DM). CVD is the major cause of
morbidity and mortality for diabetics and contributes most to the costs of diabetes.
This study was conducted to assess the prevalence of risk factors and cardiovas-
cular risk in newly diagnosed T2DM patients. METHODS: This was a prospective,
observational, questionnaire based study conducted in a tertiary care hospital.
Only newly diagnosed T2DM patients (duration of diabetes  6 months) were re-
cruited. Risk factors related to CVD in these patients were identified and the 10 year
cardiovascular risk was estimated using Framingham risk equation. RESULTS: The
results are based on a total of 152 newly diagnosed T2DM patients. The major
modifiable risk factors were identified as obesity (59%), hypertension (36%), dyslip-
idemia (26%) and overweight (24%). The prevalence of various microvascular and
macrovascular complications at the time of diagnosis was also assessed; 26% pa-
tients were found to have neuropathy followed by nephropathy in 7%. Only 5%
patients were diagnosed with coronary artery disease (CAD) along with T2DM. The
10 year CVD risk estimation showed that the females were at higher risk compared
to males (10 vs 6%). Further, the association of the cardiovascular risk with the risk
factors was analysed using binary logistic regression. The risk was found to be
significantly associated with age (55 vs 55 years) with an odds ratio of 3.38 (95%
CI 1.14-10.02; P0.03). CONCLUSIONS: The prevalence of risk factors for CVD in
newly diagnosed T2DM patients was found to be high; however, the estimated risk
was low according to the Framingham risk scoring system. Therefore, the authors
suggest that timely management of these risk factors is needed to reduce the
occurrence of CVD.
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OBJECTIVES: It is well-known that cardiovascular risk is higher in diabetes patients
but real-life country level data are scarce. The aim of this study was to compare the
cardiovascular event rate and relevant outcomes in patients with and without
diabetes in Belgium. METHODS: Event rates, average length of stay (LOS) and mor-
tality among hospitalized patients were estimated using the longitudinal IMS Hos-
pital Disease Database (2007), including data on 34.3% of Belgian hospital beds,
combined with Belgian population data. Stays were identified based on ICD-9 or
DRG coding. Acute coronary syndromes (ACS) included Myocardial infarction (ICD-
9:410-411.89) and unstable angina (ICD-9:411.1-411.8-413.0). Cerebrovascular dis-
ease (CVD) was defined as stroke (APR-DRG:045;046) and Transient Ischemic Attack
(DRG:047). Confidence intervals around relative risks (RR) were calculated to com-
pare proportions and LOS using a Wilcoxon non-parametrical test. RESULTS: In
2007 there were 10.5 million inhabitants including 450,000 diabetics. The incidence
of first ACS was 5 times higher in diabetes patients (7.7 per 1000 inhabitants vs. 1.5;
RR 5.04 [4.86-5.23]). Average LOS in diabetic ACS patients was 3 days longer (10.8 vs.
7.2 days; p0.001) and mortality during hospitalization was 38% higher (10.79% vs.
7.84%; RR 1.38 [1.14-1.66]). Recurrence within a calendar year of ACS occurred in
27% of the diabetic patients vs. 21% of the non-diabetics (RR 1.28 [1.20-1.36]). The
CVD incidence was 11.3 per 1000 inhabitants in diabetics and 2.1 per 1000 in non-
diabetics (RR: 5.26 [5.10-5.42]). In diabetic patients LOS was 4 days longer (18.5 vs.
14.5 days;p0.001), mortality during hospitalization slightly higher (9.47% vs.
8.78%; RR 1.08 [0.94-1.24]) as well as recurrence (5.11% vs. 4.62%, RR 1.11 [0.99-1.23]).
CONCLUSIONS: Patients with diabetes do not only have a significantly higher risk
of ACS and CVD, they also stay longer in the hospital, and in ACS have a signifi-
cantly higher in-hospital mortality and recurrence.
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OBJECTIVES: Turkey pharmaceutical market is a growing market in spite of gov-
ernment policies. Public pharmaceutical market rise from 7.9 billion TL to 15.5
billion TL from 2000 to 2009. In addition, Cardiovascular system medicines market
rise from 1.3 billion TL to 1.8 billion TL from 2005 to 2010. It was reported that statin
market was 21% of the cardiovascular system medicines expenditures. Statins
have the same effectiveness and safety profile. So each statin may use instead of
others. Internal reference pricing may use for statins in Turkey. The aim of the
study is to calculate possible budget impact of jumbo basket application for statins
in Turkey. METHODS: Statin consumption for year 2010 was taken from IMS. Pos-
sible 4 different budget scenarios were calculated. Scenario A defined as reimburse
all statins with the minimum statin price. Scenario B defined as reimburse all
stations up to 15% of minimum statin price. Scenario C defined as reimburse all
statins up to 10% of average price of statins. Scenario D defined as reimburse all
statins as the calculation  (average price  minimum price)/2. RESULTS: Statin
expenditure was 496 million TL in 2010. If Scenario A or B may be used, the new
statin expenditure may be 85 million or 97 million TL, respectively. If Scenario C or
D may be used, the new statin expenditure may be 320 million TL or 308 million TL,
respectively. CONCLUSIONS: However, Scenario A or B may offer maximum de-
crease in statin budget, industry may not run business under the situation. Sce-
nario C or D may be acceptable for the industry and offer government 37% or 35%
extra decrease in statin expenditure. This pilot study may spotlight possible op-
portunities in the controlling statin market budget for government.
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OBJECTIVES: Plasmid pCMV-VEGF165 is new injectable factor, activating therapeu-
tic angiogenesis in the ischemic limb and facilitating reduction of amputation rate
in Critical limb ischemia (CLI), especially in patients who cannot undergo recon-
structive arterial surgery. pCMV-VEGF165 was recently approved for use in Russia
and not yet included in government reimbursement list, therefore suitable patients
with CLI do not have general access to it. A budget impact analysis would provide
evidence to assist budget holders in decision making processes. METHODS: A bud-
get impact model was built to allow assessment of the budgetary impact to the
Federal state budget from health care system perspective if pCMV-VEGF165 is in-
troduced into state reimbursement system in 2-year time horizon. The scenarios
adopted were world (standard treatment of CLI) with and without pCMV-VEGF165.
A cohort of 26 812 patients with unreconstructable CLI was used as population
according to epidemiology data in Russian Federation. As efficacy criteria was used
amputation rates for both scenarios obtained from published sources. Direct costs
were valued in the perspective of the Russian health care system and included
diagnostics, patients routine management and pharmacotherapy. RESULTS: Ac-
cess to all patients with unreconstructable CLI pCMV-VEGF165 was resulted in
prevention of 13 674 ischemic limb amputation over a 2-year period and the budget
impact of using to new treatment option with standard treatment in patients with
unreconstructable CLI was $45 388 392. Sensitivity analysis preformed suggested
that cost of limb amputation is the most influential variable. CONCLUSIONS: Re-
sults of the present budget impact analysis suggest that introducing of pCMV-
VEGF165 into the CLI therapeutic management would significantly decrease num-
ber of limb amputations, resulting in savings in the health care budget.
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OBJECTIVES: To estimate the effectiveness of using a simple risk score comprising
only non-biochemical parameters to identify individuals more likely to incur
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